Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Unknown × TQ-B3525 × Clear all

Phase

Phase 2 5 Phase 1/2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma 1

Interventions

Cyclophosphamide 38 fludarabine 29 Injections 28 Paclitaxel 23 Gemcitabine 23 Cisplatin 22 Radiotherapy 18 toripalimab 16 pembrolizumab 15 Carboplatin 15 Capecitabine 15 Oxaliplatin 12 Fluorouracil 12 Temozolomide 11 camrelizumab 10 apatinib 10 Nivolumab 10 Docetaxel 10 Cetuximab 10 Drug Therapy 9 Irinotecan 8 Peripheral Blood Stem Cell Transplantation 7 Ipilimumab 7 Indium 7 Filgrastim 7 Dexamethasone 7 Bevacizumab 7 sintilimab 6 anlotinib 6 Vinorelbine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡